title: Polyaspartic acid coated iron oxide nanoprobes for PET/MRI imaging.
abstract: Iron oxide nanoparticles, due to their exceptional magnetic property, biocompatibility, and biodegradability, have long been studied as contrast agents for magnetic resonance imaging (Xie et al., Curr Med Chem 16(10):1278-1294, 2009; Xie et al., Adv Drug deliv Rev 62(11):1064-1079, 2010). While previous applications mostly target reticuloendothelial system (RES) organs such as liver and lymph nodes, recent efforts have been made to impart targeting peptides or antibodies onto particle surface to enable site-specific targeting after systemic administration (Xie et al., Adv Drug Deliv Rev 62(11):1064-1079, 2010; Cai and Chen, Small 3(11):1840-1854, 2007; Corot et al., Adv Drug Deliv Rev 58 (14):1471-1504, 2006; Xie et al., Acc Chem Res 44(10):883-892). Moreover, other imaging functionalities can be loaded onto nanoparticles to achieve multimodality imaging probes (Cai and Chen, Small 3(11):1840-1854, 2007; Lee et al., J Nucl Med Soc Nucl Med 49(8):1371-1379, 2008). In this protocol, we describe the procedure of constructing an iron oxide nanoparticle (IONP)-based probe with high affinity towards integrin αvβ3 for positron emission tomography (PET) and magnetic resonance imaging (MRI) dual modality imaging. The related characterizations and validation experiments, including particle concentration determination, Prussian blue staining, animal model preparation, and in vivo PET/MRI imaging will also be discussed.
authors.affiliation: University of Georgia, Athens, GA, USA.
authors.forename: Taku
authors.initials: T
authors.lastname: Cowger
authors.forename: Jin
authors.initials: J
authors.lastname: Xie
mesh_terms: D000818:Animals; D002460:Cell Line; D045744:Cell Line, Tumor; D003287:Contrast Media / Q000737:chemistry; D003301:Copper Radioisotopes; D003952:Diagnostic Imaging / Q000379:methods; D005290:Ferric Compounds / Q000737:chemistry*; D064593:Heterografts; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D053758:Nanoparticles / Q000737:chemistry*; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000648:ultrastructure; D010455:Peptides / Q000737:chemistry*; D049268:Positron-Emission Tomography / Q000379:methods*
chemical_list: D003287:Contrast Media; D003301:Copper Radioisotopes; D005290:Ferric Compounds; D039302:Integrin alphaVbeta3; D010455:Peptides; C000499:ferric oxide; C017645:polyaspartate
references.citation: Chem Rev. 2010 May 12;110(5):3087-111
references.pmid: 20225899
references.citation: Curr Med Chem. 2009;16(10):1278-94
references.pmid: 19355885
references.citation: Nucl Med Biol. 2004 Feb;31(2):179-89
references.pmid: 15013483
references.citation: J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S
references.pmid: 18523069
references.citation: Biomaterials. 2010 Apr;31(11):3016-22
references.pmid: 20092887
references.citation: J Nucl Med. 2008 Aug;49(8):1371-9
references.pmid: 18632815
references.citation: Small. 2007 Nov;3(11):1840-54
references.pmid: 17943716
references.citation: Nat Protoc. 2008;3(1):89-96
references.pmid: 18193025
references.citation: J Nucl Med. 2007 Jul;48(7):1162-71
references.pmid: 17574975
references.citation: Adv Drug Deliv Rev. 2006 Dec 1;58(14):1471-504
references.pmid: 17116343
references.citation: J Am Chem Soc. 2008 Jun 18;130(24):7542-3
references.pmid: 18500805
references.citation: J Nucl Med. 2009 Jul;50(7):1168-77
references.pmid: 19525469
references.citation: Curr Pharm Des. 2008;14(28):2943-73
references.pmid: 18991712
references.citation: Adv Drug Deliv Rev. 2010 Aug 30;62(11):1064-79
references.pmid: 20691229
references.citation: Acc Chem Res. 2011 Oct 18;44(10):883-92
references.pmid: 21548618
references.citation: Biomaterials. 2009 Dec;30(36):6912-9
references.pmid: 19773081